阿托伐他汀联合曲美他嗪治疗冠心病临床疗效观察

Atorvastatin combined with trimetazidine in the treatment of coronary heart disease

目的观察阿托伐他汀与曲美他嗪联用治疗冠心病的临床疗效。方法将2009年9月到2010年10月我院收治的冠心病患者80例随机分为对照组与治疗组,每组40例。对照组在常规治疗基础上给予曲美他嗪单独治疗;治疗组在常规治疗基础上加用曲美他嗪和阿托伐他汀联合治疗,15d为1个疗效,两组均治疗2个疗程。测定两组治疗前后的常规指标、血脂、C-反应蛋白(CRP)水平、心功能指标及血液流变学指标;评定两组治疗后的临床症状改善情况、临床疗效及不良反应发生情况。结果治疗组的血液流变学指标、心功能指标、降低血脂及CRP水平、临床症状改善均明显优于对照组(P<0.05);治疗组的显效率为67.5%、总有效率为92.5%,均明显高于对照组的52.5%和82.5%(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论阿托伐他汀与曲美他嗪联用治疗冠心病的临床疗效确切,不良反应小,值得推广应用。

Objective To discuss the clinical efficacy of atorvastatin and trimetazidine to treat coronary heart disease（CHD）.Methods 80 patients with coronary heart disease were randomly divided into control group and treatment group from September 2009 to October 2010,with 40 patients in each group.The control group was given trimetazidine,while the treatment group was given atorvastatin and trimetazidine.Both groups were treated for 2 courses,and 15 days for one course.The conventional indicators,blood lipids and C-reactive protein（CRP） levels,heart function and blood hemorheology,the changes of clinical symptoms,clinical efficacy and side effects were observed respectively.Results The hemorheology,cardiac function,lower levels of blood lipids and CRP,clinical symptoms in the treatment group were significantly better than those in the control group（P0.05）;the total effective rate was higher in treatment group than that in the control group（P0.05）;and adverse reactions difference between the two groups was not significant.Conclusion It is effective to cure CHD by using atorvastatin and trimetazidine,with few side effects.